ProMIS Neurosciences, Inc. (PMN.TO)
| Previous Close | 0.1300 |
| Open | 0.1350 |
| Bid | 0.1400 x 0 |
| Ask | 0.1450 x 0 |
| Day's Range | 0.1350 - 0.1500 |
| 52 Week Range | 0.0900 - 0.2800 |
| Volume | |
| Avg. Volume | 290,141 |
| Market Cap | 62.601M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0300 |
| Earnings Date | Nov. 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has initiated a program to develop monoclonal antibodies to treat schizophrenia and other chronic mental illnesses. Schizophrenia is a clinical t
- Baystreet
Stocks in play: ProMIS Neurosciences, Inc.
Announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on ...
- GlobeNewswire
ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment
TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the Biotech Showcase 2022 virtual panel discussion to be held on Jan. 11, 2022 from 8 AM to 9 AM PST. Eugene Williams, ProMIS Chairm
